Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn's Disease

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Crohn's Disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The study will evaluate the effectiveness and safety of a new oral medication called Zasocitinib, also known by its code name TAK-279. Participants in the study will receive either Zasocitinib or a placebo, which is a substance with no active medication, to compare the outcomes.

The purpose of the study is to assess how well Zasocitinib works in reducing the symptoms of Crohn's Disease. The study will last for a period of 52 weeks, during which participants will take the medication in capsule form. The main goal is to see if the medication can help achieve an improvement in the condition by Week 12. Participants will undergo regular check-ups and assessments to monitor their progress and any changes in their symptoms.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how the medication affects their health. The study aims to provide valuable insights into the potential benefits of Zasocitinib for individuals with moderately to severely active Crohn's Disease, contributing to the development of more effective treatments for this challenging condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be required to provide informed consent. This involves signing a document that confirms understanding of the study procedures and requirements.

    Eligibility will be confirmed based on specific criteria, including age and a diagnosis of moderately to severely active Crohn's disease.

  2. Step 2

    Screening period

    During the screening period, the participant will undergo an ileocolonoscopy with biopsies to confirm the diagnosis of Crohn's disease.

    Additional assessments may include a review of medical history and previous treatments for Crohn's disease.

  3. Step 3

    Randomization and treatment

    Participants will be randomly assigned to receive either the study medication, zasocitinib, or a placebo. Both are administered in capsule form.

    The medication is taken orally. The specific dosage and frequency will be determined by the study protocol.

  4. Step 4

    Treatment duration

    The treatment will continue for a period of 12 weeks. During this time, the participant will be monitored for any changes in their condition.

  5. Step 5

    End of treatment assessment

    At the end of the 12-week treatment period, an assessment will be conducted to evaluate the response to the medication.

    This includes an endoscopic examination to measure any changes in the severity of Crohn's disease.

  6. Step 6

    Follow-up

    After the treatment period, follow-up assessments will be conducted to monitor the participant's health and any long-term effects of the treatment.

Who can join the trial?

8 criteria

  • The person must be willing and able to understand and follow the study procedures and requirements, including using digital tools and applications. They must also provide written consent before starting any study procedures.
  • The person must be between 18 and 75 years old at the time of signing the consent form. In South Korea, the minimum age is 19 years.
  • The person must have active moderate to severe Crohn's Disease (CD) affecting specific parts of the intestine, confirmed by a score called CDAI between 220 and 450 and the presence of ulcers seen during a procedure called ileocolonoscopy.
  • The person must have a confirmed diagnosis of CD for at least 30 days before screening. This includes a biopsy report confirming the diagnosis and a report showing how long they have had the disease based on previous ileocolonoscopy.
  • If the person has a family history of colorectal cancer, is over 50 years old, or has other risk factors, they must be up to date with colorectal cancer checks, which can be done during screening.
  • The person must be willing and able to undergo an ileocolonoscopy with biopsies during screening after meeting all other criteria.
  • The person must have a history of not responding well, losing response, or not tolerating certain treatments for CD. This includes medications like 6-mercaptopurine, azathioprine, corticosteroids, or biologic agents like TNF antagonists.
  • If the person can have children and is sexually active, they must agree to use effective birth control during the study and for 10 days after the last dose of the study drug. Women must be surgically sterile, not able to have children, or use a highly effective method of contraception if sexually active with a non-sterilized partner.

Who cannot join the trial?

10 criteria

  • Patients who have other serious health conditions that could interfere with the study.
  • Patients who are currently participating in another clinical trial.
  • Patients who have had recent surgery related to Crohn's Disease.
  • Patients who have a history of not following medical advice or treatment plans.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a known allergy to the study medication or similar drugs.
  • Patients who have used certain medications that might affect the study results.
  • Patients who have a history of alcohol or drug abuse.
  • Patients who have an active infection that requires treatment.
  • Patients who have a history of cancer, except for certain types of skin cancer.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

TAK-279 is an experimental medication being studied for its potential to help people with moderately to severely active Crohn's Disease. This medication is taken by mouth and is being tested to see if it can improve the condition of the intestines as seen through an endoscope, which is a special camera used to look inside the body. The goal is to see if TAK-279 can help reduce the symptoms and inflammation associated with Crohn's Disease over a 12-week period.

What is already known about the treatment

TAK-279 – This medication is administered orally and is currently being studied in clinical trials for its effectiveness in treating moderately to severely active Crohn's Disease. It is in the investigational phase, with ongoing research to determine its safety and efficacy. The main therapeutic indication for TAK-279 is to achieve an endoscopic response in patients with active Crohn's Disease. At the molecular level, TAK-279 works by modulating specific pathways involved in inflammation, although the exact mechanism is still under investigation. It is classified pharmacologically as an anti-inflammatory agent.

Investigated diseases

Crohn's Disease – Crohn's Disease is a chronic inflammatory condition of the gastrointestinal tract, primarily affecting the small intestine and colon. It is characterized by periods of active symptoms and remission. During active phases, individuals may experience abdominal pain, diarrhea, fatigue, and weight loss. The inflammation can penetrate deep into the layers of the bowel tissue, leading to complications such as strictures or fistulas. The disease can vary in severity, with some people experiencing mild symptoms and others having more severe manifestations. The exact cause is unknown, but it is believed to involve a combination of genetic, environmental, and immune system factors.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-506704-14-00Protocol codeTAK-279-CD-2001Estimated enrolment311 patientsSponsorTakeda Development Center Americas Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.